• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Nuvation Bio Inc.

    10/27/25 4:26:56 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NUVB alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001521111
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    NUVATION BIO INC
    SEC File Number
    001-39351
    Address of Issuer
    1500 Broadway, Suite 1401
    New York
    NEW YORK
    10036
    Phone
    332-208-6102
    Name of Person for Whose Account the Securities are To Be Sold
    GARY HATTERSLEY
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    100000485000.0034227272210/27/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/27/2025Exercise of Stock OptionsIssuerCheckbox not checked10000010/27/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    10/27/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/24/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Gary Hattersley

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $NUVB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NUVB

    DatePrice TargetRatingAnalyst
    11/19/2025$12.00Buy
    B. Riley Securities
    9/30/2025$10.00Buy
    Jefferies
    4/23/2025$6.00Mkt Outperform
    Citizens JMP
    3/27/2024$1.40 → $10.00Hold → Buy
    Jefferies
    3/26/2024$5.00Neutral → Buy
    BTIG Research
    1/6/2023$5.00 → $2.00Buy → Hold
    Jefferies
    8/2/2022$8.00 → $2.50Outperform → Market Perform
    BMO Capital Markets
    8/2/2022Buy → Neutral
    BTIG Research
    More analyst ratings

    $NUVB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe

    11/3/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Participate in Upcoming Investor Conferences

    Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences: Jefferies Global Healthcare Conference on Wednesday, November 19, 2025, at 10:00 a.m. ET/3:00 p.m. GMT in London, U.K. 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 9:35 a.m. ET in Miami, FL The management team will participate in one-on-one meetings at the 2025

    10/30/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

    No targeted treatments are currently FDA approved for high-grade IDH1-mutant gliomas After a favorable meeting with FDA, protocol amendment will make G203 a Phase 3 trial to support potential registration Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced enrollment of the first patient into part 2 of G203 (NCT05303519), a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-mutant astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Safusidenib is a nove

    10/23/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Nuvation Bio with a new price target

    B. Riley Securities initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $12.00

    11/19/25 8:57:29 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Nuvation Bio with a new price target

    Jefferies initiated coverage of Nuvation Bio with a rating of Buy and set a new price target of $10.00

    9/30/25 8:57:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens JMP initiated coverage on Nuvation Bio with a new price target

    Citizens JMP initiated coverage of Nuvation Bio with a rating of Mkt Outperform and set a new price target of $6.00

    4/23/25 8:17:12 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Sjogren Colleen bought $90,350 worth of shares (50,000 units at $1.81), increasing direct ownership by 161% to 81,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:15 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF PEOPLE OFFICER Markel Stacy bought $17,100 worth of shares (10,000 units at $1.71), increasing direct ownership by 51% to 29,591 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:21 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Sauvage Philippe bought $13,216 worth of shares (7,300 units at $1.81), increasing direct ownership by 281% to 9,902 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    6/18/25 4:05:19 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    SEC Filings

    View All

    SEC Form 144 filed by Nuvation Bio Inc.

    144 - Nuvation Bio Inc. (0001811063) (Subject)

    11/20/25 4:12:36 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Nuvation Bio Inc. (0001811063) (Filer)

    11/17/25 5:31:04 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Nuvation Bio Inc.

    S-8 - Nuvation Bio Inc. (0001811063) (Filer)

    11/3/25 4:53:13 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF TECHNICAL OPERATIONS Hanley David C. exercised 200,000 shares at a strike of $1.87 and sold $1,427,680 worth of shares (200,000 units at $7.14) (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    11/21/25 4:05:06 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF MEDICAL OFFICER Liu Dongfang exercised 30,000 shares at a strike of $1.87 and sold $148,028 worth of shares (30,000 units at $4.93), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    11/19/25 4:47:31 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Hattersley Gary exercised 100,000 shares at a strike of $1.74 and sold $502,460 worth of shares (100,000 units at $5.02) (SEC Form 4)

    4 - Nuvation Bio Inc. (0001811063) (Issuer)

    10/29/25 4:24:30 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Nuvation Bio Inc.

    SC 13G/A - Nuvation Bio Inc. (0001811063) (Subject)

    11/12/24 10:32:11 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Nuvation Bio Inc.

    SC 13D/A - Nuvation Bio Inc. (0001811063) (Subject)

    10/18/24 4:15:55 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Nuvation Bio Inc.

    SC 13D - Nuvation Bio Inc. (0001811063) (Subject)

    9/10/24 4:51:38 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Financials

    Live finance-specific insights

    View All

    Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

    Successfully started 204 patients on IBTROZI™ (taletrectinib) in the third quarter of 2025 Updated data continue to show IBTROZI's unprecedented durability in TKI-naïve, advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC), with median Duration of Response (DOR) increased to 50 months as of August 2025 Enrolled first patient in global, randomized study of safusidenib with registrational intent for maintenance treatment of high-grade IDH1-mutant glioma Enrolled first patient in TRUST-IV phase 3 study of IBTROZI for the adjuvant treatment of ROS1+ early-stage NSCLC Strong balance sheet with cash, cash equivalents, and marketable securities of $549.0 million as of Septembe

    11/3/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

    Nuvation Bio Inc. (NYSE:NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host a conference call and webcast on Monday, November 3, 2025, at 4:30 p.m. ET to discuss its financial results and business updates for the third quarter of 2025. Investors and the general public are invited to listen to the live webcast and may register on the Investor Relations section of the Nuvation Bio website. To access the live conference call, participants can dial +1 833-470-1428 (U.S. toll-free) and enter access code 405112. An archived recording will be available on Nuvation Bio's website for 90 days following the event. A

    10/20/25 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

    Received U.S. Food and Drug Administration (FDA) approval for IBTROZI™ (taletrectinib), a next-generation oral treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) on June 11, 2025 Successfully started 70 patients on IBTROZI as of July 31, 2025, approximately seven weeks after U.S. FDA approval National Comprehensive Cancer Network® added taletrectinib (IBTROZI) as a Preferred Option to Clinical Practice Guidelines in Oncology for advanced ROS1+ NSCLC on June 20, 2025 Strong balance sheet with cash, cash equivalents, and marketable securities of $607.7 million as of June 30, 2025 Company to host a conference call today at 8:00 a.m. ET Nuvation Bio Inc. (

    8/7/25 7:30:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NUVB
    Leadership Updates

    Live Leadership Updates

    View All

    Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer

    Global leader with proven financial, operational, and commercial expertise joins Nuvation Bio as the company prepares to transition into a commercial-stage organization Nuvation Bio Inc. (NYSE:NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced the appointment of Philippe Sauvage as Chief Financial Officer (CFO). Mr. Sauvage brings over 20 years of global leadership experience in finance, operations, and commercialization within healthcare and biopharmaceutical organizations. Most recently, as Global Head of Operations and Access at Sanofi, he oversaw strategic segments including commercial systems, multicha

    10/7/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update

    Acquisition of AnHeart Therapeutics transformed Nuvation Bio into a late-stage, global oncology company with potential to become a commercial organization by the end of 2025 Updated data from the pivotal Phase 2 TRUST-I clinical study of taletrectinib, a ROS1 inhibitor, to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting First patient treated in a Phase 1/2 study of NUV-1511, the company's first drug-drug conjugate (DDC) to enter the clinic, for the treatment of various advanced solid tumors Strong balance sheet with cash, cash equivalents, and marketable securities of $597.0 million as of March 31, 2024 Nuvation Bio Inc. (NYSE:NUVB), a late-stage

    5/14/24 4:05:00 PM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer

    Ms. Sjogren brings nearly 30 years of biopharmaceutical experience building commercial organizations and leading successful oncology launches Pending acquisition of AnHeart Therapeutics and expanded leadership strongly positions Nuvation Bio to potentially become a commercial organization by the end of 2025 Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Colleen Sjogren as Chief Commercial Officer. Ms. Sjogren will lead the Company's commercial strategy and operations, including marketing, sales, and market access. "We are t

    3/28/24 8:00:00 AM ET
    $NUVB
    Biotechnology: Pharmaceutical Preparations
    Health Care